Clinical Utility of RASSF1A Methylation in Human Malignancies

Overview

Journal Br J Cancer

Specialty Oncology

Date 2015 Jul 10

PMID 26158424

Citations 68

Authors

A M Grawenda

E ONeill

Affiliations

Soon will be listed here.

Abstract

The high frequency of RASSF1A methylation has been noted in a vast number of patients in a broad spectrum of malignancies, suggesting that RASSF1A inactivation is associated with cancer pathogenesis. However, whether this recurrent incidence of RASSF1A hypermethylation in human malignancies and its association with more aggressive tumour phenotype is a frequent event across different cancer types has not yet been discussed. In this review, we interrogated existing evidence for association of RASSF1A hypermethylation with clinicopathological characteristics that can indicate more invasive lesions.

Citing Articles

Association of DNA methylation of RASSF1A and SHOX2 with lung cancer risk: A systematic review and meta-analysis.

Guo Y, Wu P, Liao Q, Huang Z Medicine (Baltimore). 2024; 103(50):e40042.

PMID: 39686414 PMC: 11651524. DOI: 10.1097/MD.0000000000040042.

Systematic pan-cancer analysis identified RASSF1 as an immunological and prognostic biomarker and validated in lung cancer.

Bai Y, Wang Y, Qin J, Wang T, Zhou X, Ma Z Heliyon. 2024; 10(12):e33304.

PMID: 39022053 PMC: 11253667. DOI: 10.1016/j.heliyon.2024.e33304.

New Insights into YAP/TAZ-TEAD-Mediated Gene Regulation and Biological Processes in Cancer.

Zhao Y, Sheldon M, Sun Y, Ma L Cancers (Basel). 2023; 15(23).

PMID: 38067201 PMC: 10705714. DOI: 10.3390/cancers15235497.

Multi-Functional Regulation by YAP/TAZ Signaling Networks in Tumor Progression and Metastasis.

Thrash H, Pendergast A Cancers (Basel). 2023; 15(19).

PMID: 37835395 PMC: 10572014. DOI: 10.3390/cancers15194701.

Targeted locus amplification to develop robust patient-specific assays for liquid biopsies in pediatric solid tumors.

van Zogchel L, Lak N, Gelineau N, Sergeeva I, Stelloo E, Swennenhuis J Front Oncol. 2023; 13:1124737.

PMID: 37152023 PMC: 10157037. DOI: 10.3389/fonc.2023.1124737.

References

Liu L, Kron K, Pethe V, Demetrashvili N, Nesbitt M, Trachtenberg J . Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer. 2011; 129(10):2454-62. DOI: 10.1002/ijc.25908. View

Neyaz M, Kumar R, Hussain S, Naqvi S, Kohaar I, Thakur N . Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population. Biomarkers. 2008; 13(6):597-606. DOI: 10.1080/13547500802078859. View

van der Weyden L, Adams D . The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta. 2007; 1776(1):58-85. PMC: 2586335. DOI: 10.1016/j.bbcan.2007.06.003. View

Donninger H, Vos M, Clark G . The RASSF1A tumor suppressor. J Cell Sci. 2007; 120(Pt 18):3163-72. DOI: 10.1242/jcs.010389. View

Chen H, Suzuki M, Nakamura Y, Ohira M, Ando S, Iida T . Aberrant methylation of RASGRF2 and RASSF1A in human non-small cell lung cancer. Oncol Rep. 2006; 15(5):1281-5. View

Danielsen S, Lind G, Kolberg M, Holand M, Bjerkehagen B, Hall K . Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis. Neuro Oncol. 2014; 17(1):63-9. PMC: 4416132. DOI: 10.1093/neuonc/nou140. View

Lee M, Kim H, Byun D, Lee S, Lee C, Kim J . Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res. 2001; 61(18):6688-92. View

Huang K, Huang S, Chen I, Liao C, Wang H, Hsieh L . Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clin Cancer Res. 2009; 15(12):4174-80. DOI: 10.1158/1078-0432.CCR-08-2929. View

Chan K, Lai P, Mok T, Chan H, Ding C, Yeung S . Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem. 2008; 54(9):1528-36. DOI: 10.1373/clinchem.2008.104653. View

10.

Reis-Filho J, Pusztai L . Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011; 378(9805):1812-23. DOI: 10.1016/S0140-6736(11)61539-0. View

11.

Brock M, Hooker C, Ota-Machida E, Han Y, Guo M, Ames S . DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008; 358(11):1118-28. DOI: 10.1056/NEJMoa0706550. View

12.

Wang Y, Yu Z, Wang T, Zhang J, Hong L, Chen L . Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer. 2007; 56(2):289-94. DOI: 10.1016/j.lungcan.2006.12.007. View

13.

Buhmeida A, Merdad A, Al-Maghrabi J, El-Maghrabi J, Al-Thobaiti F, Ata M . RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. Anticancer Res. 2011; 31(9):2975-81. View

14.

Arai Y, Honda S, Haruta M, Kasai F, Fujiwara Y, Ohshima J . Genome-wide analysis of allelic imbalances reveals 4q deletions as a poor prognostic factor and MDM4 amplification at 1q32.1 in hepatoblastoma. Genes Chromosomes Cancer. 2010; 49(7):596-609. DOI: 10.1002/gcc.20770. View

15.

Ha Y, Jeong P, Kim J, Kwon W, Kim I, Yun S . Tumorigenic and prognostic significance of RASSF1A expression in low-grade (WHO grade 1 and grade 2) nonmuscle-invasive bladder cancer. Urology. 2012; 79(6):1411.e1-6. DOI: 10.1016/j.urology.2012.01.042. View

16.

Yanagawa N, Tamura G, Oizumi H, Kanauchi N, Endoh M, Sadahiro M . Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer. 2007; 58(1):131-8. DOI: 10.1016/j.lungcan.2007.05.011. View

17.

Fendri A, Masmoudi A, Khabir A, Sellami-Boudawara T, Daoud J, Frikha M . Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Cancer Biol Ther. 2009; 8(5):444-51. DOI: 10.4161/cbt.8.5.7686. View

18.

Liu Y, Gao W, Siegfried J, Weissfeld J, Luketich J, Keohavong P . Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. BMC Cancer. 2007; 7:74. PMC: 1877812. DOI: 10.1186/1471-2407-7-74. View

19.

Guo C, Tommasi S, Liu L, Yee J, Dammann R, Pfeifer G . RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr Biol. 2007; 17(8):700-5. DOI: 10.1016/j.cub.2007.02.055. View

20.

Yang X, Dai W, Kwong D, Szeto C, Wong E, Ng W . Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. Int J Cancer. 2014; 136(4):E127-35. DOI: 10.1002/ijc.29192. View